UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 40

Sortiert nach

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade

Nature communications, 2021-07, Vol.12 (1), p.4319-4319, Article 4319

2021

Volltextzugriff (PDF)

Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition

Clinical cancer research, 2017-06, Vol.23 (12), p.3203-3213

2017

Volltextzugriff (PDF)

Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma

British journal of cancer, 2021-11, Vol.125 (10), p.1365-1376

2021

Volltextzugriff (PDF)

Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer

International journal of cancer, 2013-08, Vol.133 (4), p.898-907

2013

Volltextzugriff (PDF)

Dissecting loss of heterozygosity (LOH) in neurofibromatosis type 1-associated neurofibromas: Importance of copy neutral LOH

Human mutation, 2011-01, Vol.32 (1), p.78-90

2011

Volltextzugriff (PDF)

Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations

Human mutation, 2009-03, Vol.30 (3), p.454-462

2009

Volltextzugriff (PDF)

Abstract 998: Searching for genetic alterations that drive the capability of evading tumor immunosurveillance in lung cancer

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.998-998

2020

Volltextzugriff (PDF)

MET-oncogenic and JAK2-inactivating alterations are independent factors that affect regulation of PD-L1 expression in lung cancer

Clinical cancer research, 2018-09, Vol.24 (18), p.4579-4587

2018

Volltextzugriff (PDF)

MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1

Cancer discovery, 2014-03, Vol.4 (3), p.292-303

2014

Volltextzugriff (PDF)

HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2024-03, Vol.189, p.107502-107502, Article 107502

2024

Volltextzugriff (PDF)

Biological and clinical perspectives of the actionable gene fusions and amplifications involving tyrosine kinase receptors in lung cancer

Cancer treatment reviews, 2022-09, Vol.109, p.102430-102430, Article 102430

2022

Volltextzugriff (PDF)

Abstract 1765: Molecular and immunological characterization of non-small cell lung cancer harboring cMET alterations

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1765-1765

2017

Volltextzugriff (PDF)

Nature and mRNA effect of 282 different NF1 point mutations: focus on splicing alterations

Human mutation, 2008-09, Vol.29 (9), p.E173-E193

2008

Volltextzugriff (PDF)

Abstract 111: PIK3R1 gene alterations, insights on its role in lung cancer

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.111-111

2012

Volltextzugriff (PDF)

Deep analysis of acquired resistance to FGFR1 inhibitor identifies MET and AKT activation and an expansion of AKT1 mutant cells

Oncotarget, 2018-07, Vol.9 (59), p.31549-31558

2018

Volltextzugriff (PDF)

Abstract 3277: SWI/SNF inactivation vulnerability

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.3277-3277

2022

Volltextzugriff (PDF)

Massive parallel DNA pyrosequencing analysis of the tumor suppressor BRG1/SMARCA4 in lung primary tumors

Human mutation, 2011-02, Vol.32 (2), p.E1999-E2017

2011

Volltextzugriff (PDF)

MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer

Cell reports. Medicine, 2023-04, Vol.4 (4), p.101006-101006, Article 101006

2023

Volltextzugriff (PDF)

Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition

Clinical cancer research, 2017-06, Vol.23 (12), p.3203-3213

2017

Volltextzugriff (PDF)

Abstract A35: MAX inactivation in small cell lung cancer disrupts the MYC-SWI/SNF programs and is synthetic lethal with BRG1

Molecular cancer research, 2015-10, Vol.13 (10_Supplement), p.A35-A35

2015

Volltextzugriff (PDF)

Abstract 2477: Max inactivation in small cell lung cancer disrupts the MYC-SWI/SNF programs and is synthetic lethal with BRG1

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.2477-2477

2014

Volltextzugriff (PDF)

Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2 genes

Breast cancer research and treatment, 2012-04, Vol.132 (3), p.979-992

2012

Volltextzugriff (PDF)

Abstract 3034: Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.3034-3034

2013

Volltextzugriff (PDF)

Modulation of aberrant NF1 pre-mRNA splicing by kinetin treatment

European journal of human genetics : EJHG, 2010-05, Vol.18 (5), p.614-617

2010

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(39)

Publikationsform

Artikel
(40)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade

Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition

Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma

Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer

Dissecting loss of heterozygosity (LOH) in neurofibromatosis type 1-associated neurofibromas: Importance of copy neutral LOH

Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations

Abstract 998: Searching for genetic alterations that drive the capability of evading tumor immunosurveillance in lung cancer

MET-oncogenic and JAK2-inactivating alterations are independent factors that affect regulation of PD-L1 expression in lung cancer

MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1

HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer

Biological and clinical perspectives of the actionable gene fusions and amplifications involving tyrosine kinase receptors in lung cancer

Abstract 1765: Molecular and immunological characterization of non-small cell lung cancer harboring cMET alterations

Nature and mRNA effect of 282 different NF1 point mutations: focus on splicing alterations

Abstract 111: PIK3R1 gene alterations, insights on its role in lung cancer

Deep analysis of acquired resistance to FGFR1 inhibitor identifies MET and AKT activation and an expansion of AKT1 mutant cells

Abstract 3277: SWI/SNF inactivation vulnerability

Massive parallel DNA pyrosequencing analysis of the tumor suppressor BRG1/SMARCA4 in lung primary tumors

MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer

Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition

Abstract A35: MAX inactivation in small cell lung cancer disrupts the MYC-SWI/SNF programs and is synthetic lethal with BRG1

Abstract 2477: Max inactivation in small cell lung cancer disrupts the MYC-SWI/SNF programs and is synthetic lethal with BRG1

GENOMIC PROFILING OF PATIENT-DERIVED XENOGRAFTS FOR LUNG CANCER IDENTIFIES B2M INACTIVATION IMPAIRING IMMUNORECOGNITION

Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2 genes

Abstract 3034: Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer

Modulation of aberrant NF1 pre-mRNA splicing by kinetin treatment

Suchergebnisse filtern